News Briefs

16 May 2009 Print this article Comments Share this article
Recombinant human Relaxin disappoints in Scleroderma trial In a study of patients with systemic sclerosis with diffuse cutaneous involvement, treatment with recombinant human relaxin did not improve skin disease or reduce functional disability....

Want to read complete article? Please Sign in or Register.

Most viewed articles this week

Recent comments

Related sites